Trial Profile

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasatinib (Primary)
Indications Cancer; Chronic myeloid leukaemia; Prostate cancer
Focus Therapeutic Use
Sponsors Bristol-Myers Squibb

Most Recent Events

06 Apr 2023 Status changed from active, no longer recruiting to completed.
15 Oct 2022 This trial has been completed in Poland (Date of the global end of the trial : 13-May-2022), according to European Clinical Trials Database record.
02 Dec 2021 Planned End Date changed from 1 Jan 2022 to 31 Mar 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com